Search PubMed⌕ Search

Biomedical subjects

S Goto

Publications and source records attributed to S Goto.

At least 1,009 records · Page 56Linked to original sources
PubMed1984

Determination of low affinity platelet factor 4 in frozen and thawed human platelets by the newly developed enzyme immunoassay system.

By the use of a newly developed sandwich enzyme immunoassay method for low affinity platelet factor 4 (LA-PF4), the effects of repeated freeze-thawing on the contents of this protein in platelets were determined and compared with those of Triton-X 100 lysed platelets. The assay system consisted of polystyrene balls covered with immobilized antibody fragments F(ab')2 and the same antibody Fab' labeled with beta-D-galactosidase from E. coli. The assay was specific to LA-PF4 with no significant cross-reactivity with platelet factor 4. Coefficients of variation within-run and between-run for the assay of LA-PF4 were less than 12%. The results obtained with this enzyme immunoassay correlated well with those of a radioimmunoassay of beta-thromboglobulin which is immunologically identical with LA-PF4 (r = 0.961, slope = 1.056, y-intercept = -3.739 ng/ml; n = 22). The contents of LA-PF4 per 10(9) Triton-X 100 lysed platelets in platelet-rich plasma were 23.65 +/- 3.14 micrograms (mean +/- S.D.). The contents of LA-PF4 in platelets were increased from 46% to 95% of Triton-X 100 values by repeated freezing and thawing 1 to 7 times. The present data indicate that the freeze-thawing technique should be done carefully to obtain the reliable determination of LA-PF4 in platelets.

Blood Coagulation Factors↗
PubMed1984

High yield of platelet-rich plasma from CPD blood compared to ACD blood.

The yields of platelet-rich plasma (PRP) obtained by centrifugation of CPD (citrate-phosphate-dextrose) blood and ACD (acid-citrate-phosphate) blood were compared. The volumes of PRP from 5 ml blood in test tubes and 200 ml blood in bags were larger by 4% and 4.5%, respectively, when CPD was used as an anticoagulant. In addition, the number of platelets in PRP from CPD blood was higher than that from ACD blood. These data suggest that the optimal centrifugal condition for CPD blood should be different from that for ACD blood.

Blood Platelets↗
PubMed1984

High yield of platelet-rich plasma from CPD blood compared to ACD blood.

The yields of platelet-rich plasma (PRP) obtained by centrifugation of CPD (citrate-phosphate-dextrose) blood and ACD (acid-citrate-phosphate) blood were compared. The volumes of PRP from 5 ml blood in test tubes and 200 ml blood in bags were larger by 4% and 4.5%, respectively, when CPD was used as an anticoagulant. In addition, the number of platelets in PRP from CPD blood was higher than that from ACD blood. These data suggest that the optimal centrifugal condition for CPD blood should be different from that for ACD blood.

Blood Platelets↗
PubMed1984

The acetylation of 6'-amino group of amikacin by a new enzyme prepared from serratia sp.

It was found that Serratia marcescens 43, Serratia proteamaculans 48 and Serratia sp. 45, all of which were clinically isolated, produced a new type of aminoglycoside acetyltransferase which acetylated amikacin at the 6'-amino group. 1-N-[(S)-3-Amino-2-hydroxypropionyl]-gentamicin B (HAPA-B, SCH 21420) and gentamicin C2 were hardly inactivated by the enzymes and had effective antimicrobial activities against these strains both in vitro and in vivo. This kind of aminoglycoside acetyltransferase should be classified into a new group other than previously reported AAC(6') enzymes.

Acetylation↗
PubMed1984

[Cerebral metastasis of choriocarcinoma].

One hundred and eighty-two cases of choriocarcinoma were treated in our clinic during the 26 years period from 1957 to 1982. Forty-one patients among them (2.3%) had cerebral metastases. Analysis on the autopsy findings of patients with cerebral metastases of choriocarcinoma proved neurosurgical resectability in most cases. Craniotomy and removal of cerebral metastatic lesion has been adopted since 1972, and a significant difference was noted in the surviving time between surgically treated group and the group without surgery. The risk factors for developing brain metastases were analyzed. Patients whose uterine lesion showed immature type of histopathology (p less than 0.01), patients without uterine lesion (p less than 0.05) and patients with pulmonary metastasis (p less than 0.01) had higher risk of developing cerebral metastasis.

Adolescent↗
PubMed1984

In vitro antibacterial activity and beta-lactamase stability of cefodizime, a new cephalosporin antibiotic.

The in vitro activity and beta-lactamase stability of cefodizime (HR 221), a new cephalosporin, were compared with those of other cephem antibiotics. HR 221 was highly active against Gram-negative bacteria. The compound inhibited growth of all tested Haemophilus influenzae strains at 0.10 microgram/ml and showed strong activity even against penicillin-resistant Neisseria gonorrhoeae strains, but it was less effective against Pseudomonas aeruginosa than the other antibiotics tested. Against Gram-positive bacteria, HR 221 showed 100% inhibition of growth of Streptococcus pneumoniae at 0.39 microgram/ml, and it was slightly less active against Staphylococcus aureus (MIC90:12.5 micrograms/ml) than other antibiotics such as cefotaxime (CTX). The bactericidal activity of HR 221 against E. coli was dose-related and comparable to that of CTX, cefoperazone and latamoxef. The bactericidal activity of the compound at medium concentrations simulating human serum levels was higher than that of CTX and cefmetazole, and no cell regrowth was noted after beta-lactamase-induced inactivation of the compound. HR 221 was stable to most drug-inactivating enzyme preparations from various bacterial species.

Cefoperazone↗
PubMed1984

In vivo antibacterial activity of cefodizime, a new cephalosporin antibiotic.

The in vivo activity of cefodizime (HR 221) was compared with that of cefotaxime (CTX), cefmenoxime, latamoxef, cefazolin and cefmetazole (CMZ). The protective effects of HR 221 on experimental infections in mice caused by Staphylococcus aureus Smith, Escherichia coli C-11, Proteus vulgaris GN-76 and Serratia marcescens No. 2 were directly related to its in vitro activity against these strains. In contrast, the compound showed the smallest ED50 values, among the 5 antibiotics tested (not including CMZ), for Klebsiella pneumoniae 3K-25 and Pseudomonas aeruginosa PI 67 against which it had relatively low in vitro activity, and its ED50 for Citrobacter freundii GN-346 was as small as 1.821 mg/mouse in spite of its MIC of greater than 100 micrograms/ml. HR 221 exerted potent bactericidal activity against Streptococcus pneumoniae Sp-1 inoculated into the mouse lung; the duration of action was prolonged. When tested against the E. coli Ec-89 infection induced in the rat uterus, the activity of HR 221 given to rats once daily was equal to that of CTX or CMZ given at the same dose twice daily.

Animals↗
PubMed1984

[Immuno-capacity in the patients with trophoblastic tumors].

In patients with trophoblastic tumors, changes in immuno-capacity through their clinical courses were examined, by 1) 3H-thymidine uptake by PHA-stimulated peripheral lymphocytes using whole blood microculture assay (common cellular immunity), and 2) the effects of patients' sera to 3H-thymidine uptake by PHA-stimulated peripheral blood lymphocytes (humoral factor). Hydatidiform mole: After molar delivery, cellular immunity accelerated, and humoral suppressive factor significantly increased. Invasive mole: No significant change was observed in the cellular immunity, but humoral suppressive factors increased gradually as the therapies proceeded. And the suppressive apex came at about the 60th day of admission, but these factors decreased afterwards. Choriocarcinoma: At initial time, cellular immunity accelerated significantly, and from the 60th day to the 90th day of admission, this cellular immunity declined significantly compared with that in the pretreated state. But cellular immunity was not entirely eliminated by the courses of treatment. The humoral suppressive apex came at about the 120th day of admission. Nevertheless, where death unfortunately occurred, humoral suppressive factors were not so numerous. As a whole, from the viewpoint of immunotherapy in patients with choriocarcinoma, common immunity which was observed in this study did not decline, so that specific immunotherapy must be regarded as likely kept in mind.

Female↗
PubMed1984

Studies on the mode of delivery and the outcome of small preterm infants with less than 32 weeks of gestation.

The purpose of this study is to make the relationship clear between the mode of delivery and the outcome of small preterm infants. A total of 91 tiny infants who were delivered before 32 weeks of gestation at Seirei Hamamatsu Hospital (between July 1, 1977 and January 31, 1983) and were studied retrospectively. Mean and standard deviation of birth weight and gestational age were 1215 +/- 388 grams and 28.2 +/- 2.4 weeks. The following results were obtained in the present study: 1) breech vaginal delivery of a tiny infant was a associated with an alarmingly high neonatal mortality rate, 2) infants weighing less than 750 grams had a very low survival rate among any of the modes of delivery, 3) infants delivered before 28 weeks of gestation had a poor survival rate, 4) an elective cesarean section of the infants weighing between 750 and 1499 grams showed a lower 28 days mortality rate than an emergency cesarean section or a breech vaginal delivery, though there were no statistical differences between a cephalic vaginal delivery and an elective cesarean section, 5) the frequency of intracranial hemorrhage was significantly lower among the elective cesarean sections than the others.

Birth Weight↗
PubMed1984

[Specific in vitro effects of methotrexate entrapped into liposomes bearing antibody fragments against human chorionic gonadotropin on cell growth of cultured human choriocarcinoma cells].

Methotrexate (MTX) was entrapped into liposomes, to which rabbit antibody fragments (Fab') against human chorionic gonadotropin (hCG) had been coupled covalently, using N-[4-(p-maleimidophenyl) butyryl] phosphatidyl ethanolamine. By this system, The resulting molar ratio in the prepared liposomes was 15 MTX per Fab', and the activities of both MTX and the antibody were well preserved. The inhibitory effects of MTX entrapped in liposomes bearing anti-hCG Fab' (Lip[MTX, anti-hCG]) on the growth of choriocarcinoma cells (BeWo) in vitro were examined. The 50% inhibitory concentration of Lip[MTX, anti-hCG] was found to be 1 X 10(-3) micrograms MTX/ml, which was significantly lower than the concentrations of control groups, free MTX (2.5 X 10(-3) micrograms/ml) or MTX entrapped in liposomes bearing no antibody (Lip [MTX], 1.3 X 10(-2) micrograms/ml). The effect of the coupling of the specific antibody was more clearly demonstrated by a short-time incubation (60 min) experiment. Lip [MTX, anti-hCG] exhibited marked inhibition on cell growth, compared to MTX entrapped in liposomes bearing non-immunized Fab' (Lip[MTX, non-immunized Fab']). On the other hand, free MTX showed no effect in this experiment. We may conclude that Lip [MTX, anti-hCG] has a specific inhibitory effect on the growth of choriocarcinoma cells in vitro, which suggests the possibility of a specific immunochemotherapy for this disease, using the specific antibody to this tumor coupled to liposomes.

Antibodies↗